These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7583915)
21. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732 [TBL] [Abstract][Full Text] [Related]
22. Differential reactivities of antibodies to HIV and HTLV-I in sera of suspected AIDS and ARC patients. Aidoo M; Nishiwaki O; Akari H; Brandful JA; Ampofo W; Hayami M; Ayisi NK West Afr J Med; 1994; 13(3):150-1. PubMed ID: 7841103 [TBL] [Abstract][Full Text] [Related]
23. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. Orosz CG; Zinn NE; Olsen RG; Mathes LE J Immunol; 1985 May; 134(5):3396-403. PubMed ID: 2984289 [TBL] [Abstract][Full Text] [Related]
24. Serum suppression of lymphocyte activation in vitro in acquired immunodeficiency disease. Cunningham-Rundles S; Michelis MA; Masur H J Clin Immunol; 1983 Apr; 3(2):156-65. PubMed ID: 6853684 [No Abstract] [Full Text] [Related]
25. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658 [TBL] [Abstract][Full Text] [Related]
26. Preparation and characterization of human HIV type 1 neutralizing reference sera. Vujcic LK; Quinnan GV AIDS Res Hum Retroviruses; 1995 Jul; 11(7):783-7. PubMed ID: 7546904 [TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445 [TBL] [Abstract][Full Text] [Related]
28. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS. Page M; Vella C; Corcoran T; Dilger P; Ling C; Heath A; Thorpe R AIDS; 1992 May; 6(5):441-6. PubMed ID: 1616648 [TBL] [Abstract][Full Text] [Related]
29. [Antigens of the human immunodeficiency virus in serum of high risk people in the city of Monterrey]. Salinas Carmona MC; Flores de Castañeda MS; Garza Elizondo MA; Pérez Rivera LI Rev Invest Clin; 1989; 41(2):129-32. PubMed ID: 2781175 [TBL] [Abstract][Full Text] [Related]
30. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275 [TBL] [Abstract][Full Text] [Related]
31. p24 antibody production in p24 antibody-negative HIV-infected subjects. Stickler MC; Sharpe S; Zolla-Pazner S Viral Immunol; 1992; 5(2):123-32. PubMed ID: 1616583 [TBL] [Abstract][Full Text] [Related]
32. Prevalence and specificity of lymphocytotoxic antibodies in different stages of HIV infection. Szabó B; Tóth FD; Kiss J; Füst G; Ujhelyi E; Bánhegyi D; Horváth A; Hollán SR Acta Virol; 1992 Aug; 36(4):392-400. PubMed ID: 1362323 [TBL] [Abstract][Full Text] [Related]
33. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. Montefiori DC; Lefkowitz LB; Keller RE; Holmberg V; Sandstrom E; Phair JP AIDS; 1991 May; 5(5):513-7. PubMed ID: 1863402 [TBL] [Abstract][Full Text] [Related]
34. Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors. Rusconi S; Berlusconi A; Papagno L; Colombo MC; De Maddalena C; Riva A; Bagnarelli P; Balotta C; Galli M Clin Immunol Immunopathol; 1997 Dec; 85(3):320-3. PubMed ID: 9400632 [TBL] [Abstract][Full Text] [Related]
35. [Detection of HIV antibody and antigen]. Tsaihong JC; Ma P Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 Nov; 22(4):286-91. PubMed ID: 2637106 [TBL] [Abstract][Full Text] [Related]
36. Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS; Schable C; Koch W; Do AN; Spira T; Lansky A; Ellenberger D; Lal RB; Hyer C; Davis R; Marx M; Paul S; Kent J; Armor R; McFarland J; Lafontaine J; Mottice S; Cassol SA; Michael N AIDS; 1999 Jan; 13(1):89-96. PubMed ID: 10207549 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of AIDS-associated retrovirus and antibodies among male homosexuals at risk for AIDS in Greenwich Village. Casareale D; Dewhurst S; Sonnabend J; Sinangil F; Purtilo DT; Volsky DJ AIDS Res; 1984-1985; 1(6):407-21. PubMed ID: 6085926 [TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibodies and serum interferon levels in the different stages of HIV infection. Szabó B; Tóth FD; Kiss J; Ujhelyi E; Füst G; Horváth A; Hollán SR Acta Virol; 1990 Apr; 34(2):164-70. PubMed ID: 1975977 [TBL] [Abstract][Full Text] [Related]
40. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Goudsmit J; Ljunggren K; Smit L; Jondal M; Fenyö EM Arch Virol; 1988; 103(3-4):189-206. PubMed ID: 3265052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]